Replimune Share Price

Replimune Share Price

NASDAQ: REPL | Small Cap | Healthcare
$19.80
+$0.11 (0.56%) Last updated on 19 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Replimune Stock Performance

Open
$19.75
Prev. Close
$19.69
Circuit Range
N/A
Day Range
$19.36 - $20.11
Year Range
$1.50 - $23.39
Volume
89,956
Average Traded
$19.85

Replimune Share Price Today

As of 19 November 2026, Replimune Group, Inc.'s share price is $19.80. The stock opened at $19.75, compared to its previous close of $19.69. During today's trading session, Replimune Group, Inc.'s share price traded between $19.36 and $20.11, with an average price of $19.74. Over the past 52 weeks, the stock has recorded a high of $23.39 and a low of $1.50. In terms of performance, Replimune Group, Inc.'s share price has risen by 127.59% over the last six months and is up 97.80% on a year-on-year basis.

Replimune Share Price Chart

Line chart of the Replimune price trend over the selected period. The price rose overall, ranging from 19.36 to 20.11, ending at 19.80.
$19.36$20.11
L
Show Current Price
H

Replimune Stock Fundamentals & Key Indicators

Market Cap
$1.60B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.86
Revenue (TTM)
$0.00
Return On Equity (TTM)
-132.36%
Profit Margin
N/A
Debt to Equity
0.61
Quarterly Earnings Growth YoY
19.47%

Replimune Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$70.93-$73.22-$69.77-$57.12
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-3.23%4.71%18.13%

Replimune Annual Profit & Loss

All figures in USD

Particulars2023202420252026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$174.28-$215.79-$247.30-$313.94
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-23.82%-14.60%-26.95%

Replimune Balance Sheet

All figures in USD Million

Particulars2026202520242023
Non Current Assets53.2755.4554.0653.99
Current Assets279.12495.88433.67592.6
Total Assets332.39551.33487.72646.59
Non Current Liabilities108.073.1272.7857.47
Current Liabilities58.2362.3640.4433.83
Total Liabilities166.23135.49113.2191.3
Shareholders' Equity166.16415.84374.51555.29

Replimune Cash Flow

Annually

All figures in USD Million

Particulars2026202520242023
Operating-280.34-192.25-185.47-128.05
Investing310.84-23.897.2-142.5
Financing66.29252.416.28311.3

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Replimune Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$18.00
$19.79
+12.57%
Oct 2026
$13.10
$17.57
+32.54%
Sep 2026
$15.37
$13.26
-15.00%
Aug 2026
$11.27
$15.60
+39.22%
Jul 2026
$11.45
$11.21
+1.31%
Jun 2026
$8.95
$11.06
+27.13%
May 2026
$2.52
$8.70
+240.51%
Apr 2026
$7.78
$2.56
-66.56%
Mar 2026
$7.55
$7.64
-0.20%
Feb 2026
$6.93
$7.66
+9.05%
Jan 2026
$9.71
$7.02
-27.70%
Dec 2025
$10.00
$9.71
-3.00%

Replimune Share Price FAQs